Bristol Myers Squibb is expanding a partnership with oncology organization Sarah Cannon Research Institute, tapping into SCRI ...
BMS and J&J first linked together in 2018 to develop factor X1a inhibitors as anti-coagulants. The three Phase III Librexia ...
The TV ad will run through Nov. 16 across major cable channels, including CNN, Fox News and ESPN, a BMS spokesperson told ...
On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is serving up mixed results for the first three months of the year. Still, even as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback